Eloxx Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. The filing was signed August 11, 2023. Eloxx is a clinical-stage biopharmaceutical company developing ribosome-modulating drug candidates for rare genetic diseases and has not generated revenue from product or service sales.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $2.338 million | $7.651 million | $5.826 million | $15.550 million |
| General and administrative expense | $1.802 million | $2.645 million | $3.797 million | $5.699 million |
| Total operating expenses | $4.140 million | $10.296 million | $9.623 million | $21.249 million |
| Net loss | $4.341 million | $10.618 million | $10.571 million | $22.238 million |
| Net loss per share, basic and diluted | $1.96 | $4.90 | $4.83 | $10.27 |
There was no revenue, so a revenue margin is not meaningful. Operating cash use was $8.880 million for the first half, compared with $19.238 million a year earlier. Cash, cash equivalents and restricted cash declined to $4.541 million from $19.468 million at year-end 2022; cash and cash equivalents alone were $4.331 million.
At June 30, current assets were $5.382 million and current liabilities were $21.251 million, a working-capital deficit of approximately $15.869 million. Total liabilities were $24.589 million and stockholders’ deficit was $18.596 million. Hercules debt was $5.0 million principal, with a $4.791 million carrying value before the separately reported maturity fee. The loan bears a 14.5% stated rate at quarter-end (19.2% effective rate); principal payments were scheduled to begin September 1, 2023, with maturity April 1, 2025. Advances from collaboration partners included $12.535 million recorded as a current liability.
Changes versus prior period
- First-half operating expenses fell 55% and net loss fell 52% year over year. The largest reduction was R&D expense, reflecting lower preclinical spending on inhaled ELX-02 for cystic fibrosis and reduced Cystic Fibrosis Foundation (CFF)-funded activity. Lower G&A spending also reflected reduced personnel, professional-fee, stock-compensation, and facility costs.
- Operating cash use was lower than in the prior-year half, but 2023 financing included a $7.5 million Hercules principal repayment, partly offset by $1.428 million net proceeds from ATM share sales. The prior-year period included $7.0 million of CFF advances.
- In March 2023, the Hercules amendment reduced the minimum qualified-cash covenant to $2.25 million, extended the interest-only period to September 1, 2023, and required repayment of $7.5 million principal. The company reported compliance with debt covenants at June 30.
Outlook, developments and risks
- Going concern and funding: Management said quarter-end cash, together with $1.7 million gross ATM proceeds and a $0.2 million CFF milestone payment received after quarter-end, would not fund current and planned operations for the next 12 months. The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Additional financing is needed but is not assured; failure to obtain it could force reductions, delays, or termination of development programs.
- Equity financing and dilution: The Oppenheimer ATM agreement has a stated $50 million program, but the filing notes an applicable Form S-3 offering limit of $6.5 million as of the prospectus supplement. By the filing date, $3.4 million had been sold under the program; $1.7 million gross was sold after June 30. Q2 sales comprised 326,310 shares for $1.7 million gross proceeds, or a weighted-average $5.20 per share, and $1.428 million net after issuance costs. Further equity financing could dilute existing holders.
- Pipeline: ELX-02 is in a Phase 2 Alport syndrome trial. Three patients received two months of treatment; the company reported approximately 50% lower proteinuria in one patient and a rebound after treatment withdrawal. In August 2023, it reported kidney-biopsy electron microscopy findings interpreted as improvement in all three patients and said it intended to advance toward a pivotal trial, subject to funding. These results are from a very small study and do not establish efficacy or approval.
- Cystic fibrosis: The company paused ELX-02 CF development after its Phase 2 combination trial did not achieve statistical significance on efficacy endpoints. The CFF stopped funding the program in September 2022; $7.2 million of the amended award was no longer available under the current program. A $0.2 million closeout milestone was received in July 2023.
- ZKN-013: The FDA cleared the IND for a single-ascending-dose trial in healthy volunteers for potential RDEB treatment. Further dose escalation and development remained dependent on trial results, FDA discussions, and available funding. The filing also describes preclinical programs in JEB and FAP.
- Nasdaq listing: The company had not met Nasdaq’s $35 million minimum market value of listed securities requirement. On August 3, 2023, the Nasdaq Hearings Panel extended the compliance period through October 9, 2023, subject to milestones in the company’s compliance plan. Delisting could impair access to capital and trading liquidity.
- Other risks and controls: Risks include continued operating losses, clinical and regulatory uncertainty, adverse events, limited access to financing, debt covenant compliance, and potential dilution. Management reported disclosure controls were effective as of June 30, 2023, with no material change in internal control over financial reporting during the quarter. The company reported no material pending legal proceedings.
Guidance: The filing provides no numerical revenue, earnings, or cash-flow guidance. Management expects continued losses and significant expenses and says planned operations require additional capital.
Most important facts for investors to verify
- Current cash runway, financing progress, and the remaining amount available under the ATM after applicable registration limits and subsequent sales.
- Nasdaq compliance-plan milestones and whether the company met the October 9, 2023 deadline.
- Complete Alport Phase 2 data, including safety, durability, and the basis for advancing to a pivotal trial.
- Hercules repayment schedule, covenant headroom, and the company’s ability to meet scheduled principal and interest payments.
- Future development plans and funding for ELX-02 in CF and ZKN-013, including any new CFF support or other partnerships.